Curis Lifesciences Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Curis Lifesciences Ltd is ₹ 116.5 as of 06 May 15:30 . The P/E Ratio of Curis Lifesciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 21 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Curis Lifesciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 13.28 crore on March 2021 to ₹ 15.8 crore on March 2025 . This represents a CAGR of 3.54% over 5 years The Revenue of Curis Lifesciences Ltd is ₹ 9.12 crore as of Jun '24 .The Revenue of Parmax Pharma Ltd is ₹ 0 crore as of Jun '24 . The EBITDA of Curis Lifesciences Ltd is ₹ 2.73 crore as of Jun '24 .The EBITDA of Parmax Pharma Ltd is ₹ 0 crore as of Jun '24 . The Net Profit of Curis Lifesciences Ltd is ₹ 1.2 crore as of Jun '24 .The Net Profit of Parmax Pharma Ltd is ₹ 0 crore as of Jun '24 . The Dividend Payout of Curis Lifesciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Curis Lifesciences Ltd

Curis Lifesciences Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name and style of 'M/s Loreto Pharmaceutacals', pursuant to a Deed of Partnership dated 2 June, 2010.
Thereafter ' M/s Loreto Pharmaceutacals' was converted from Partnership Firm to a Private Limited Company as 'Curis Lifesciences Private Limited' and received a Certificate of Incorporation dated on March 23rd, 2016 issued by Registrar of Companies, Ahmedabad.
Subsequently, Company was converted into a Public Limited Company and the name of the Company was changed from 'Curis Lifesciences Private Limited' to 'Curis Lifesciences Limited' vide certified incorporated upon the conversion dated August 9, 2024, issued by the Central Processing Centre, Manesar. Company's business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic.

About Parmax Pharma Ltd

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations.
The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Curis Lifesciences Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Curis Lifesciences Ltd or Parmax Pharma Ltd?

Market cap of Curis Lifesciences Ltd is 97 Cr while Market cap of Parmax Pharma Ltd is 11 Cr

What are the key factors driving the stock performance of Curis Lifesciences Ltd and Parmax Pharma Ltd?

The stock performance of Curis Lifesciences Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Curis Lifesciences Ltd and Parmax Pharma Ltd?

As of May 6, 2026, the Curis Lifesciences Ltd stock price is INR ₹121.0. On the other hand, Parmax Pharma Ltd stock price is INR ₹32.0.

How do dividend payouts of Curis Lifesciences Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Curis Lifesciences Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.